Pharma & Biotech - Page 16

Outside advisers to the US Food and Drug Administration have recommended relaxing restrictions on a series of popular peptide compounds sought after in wellness circles. The advisory panel delivered its recommendations following

Johnson & Johnson has reported strong phase 3 results combining its bispecific antibody Talvey with Darzalex Faspro in earlier-stage multiple myeloma patients. The data emerged from J&J’s MonumenTAL-3 phase 3 study, which

Cardinal Health (NYSE: CAH) has announced two definitive agreements totalling approximately $360 million in cash to expand its at-Home Solutions division. The company is acquiring the Diabetes Health business of AdaptHealth Corp.

ARS Pharmaceuticals (Nasdaq: SPRY) has announced a new collaboration with former NFL quarterback and 2026 Hall of Fame inductee Drew Brees to raise awareness about severe allergic reactions. The campaign centres on

GSK plc has secured its first-ever approved medicine in lung cancer after the US FDA granted approval to Jideytro (zidesamtinib) for adult patients with previously treated ROS1-positive non-small cell lung cancer. The

Healthcare’s long-promised overhaul of prior authorisation remains a work in progress, with frontline physicians reporting limited improvements despite industry pledges and new federal requirements. A new American Medical Association survey found that

President Donald Trump has announced a phased tariff plan targeting generic drugs imported into the United States, beginning with a zero-tariff window starting August 1. Under the plan, generic drug imports will

Doceree has unveiled Semmelweis, a proprietary artificial intelligence reasoning and orchestration model built exclusively for pharmaceutical commercialisation and marketing. The model serves as the intelligence layer powering Daily Command, Doceree’s newly launched

Sanofi has unveiled a revised executive lineup set to take effect on 1 September, as newly installed CEO Belén Garijo moves to reshape leadership across the organisation. Garijo, a former CEO of